5 Most Undervalued NYSE Stocks to Invest In

4. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 83

Pfizer Inc. (NYSE:PFE) is one of the most undervalued NYSE stocks to invest in. On June 18, Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15 to pursue a new professional opportunity in the consumer goods industry. The company has appointed Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, to serve as interim Chief Financial Officer effective August 16 while a search for a permanent successor is conducted.

Chairman and CEO Albert Bourla thanked Denton for his leadership during pivotal business transactions, including the acquisitions of Seagen, Biohaven, and Metsera, which are expected to support Pfizer’s long-term growth. Bourla expressed confidence in Guegan’s ability to lead the finance organization and maintain focus on the company’s strategic execution and commitment to shareholders.

Cecile Guegan brings over two decades of experience to the role, having led financial operations across complex strategic portfolios and research and development at Pfizer Inc. (NYSE:PFE). Most recently, she oversaw the financial operations of the biopharmaceutical business and managed the integration of Seagen in 2024, providing her with the institutional knowledge required for her new interim responsibilities.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets, and is also involved in developing immunotherapies that help the immune system to recognise and attack cancer cells.